Welcome to our dedicated page for BrightSpring Health Services news (Ticker: BTSG), a resource for investors and traders seeking the latest updates and insights on BrightSpring Health Services stock.
BrightSpring Health Services, Inc. (NASDAQ: BTSG) is a healthcare company that focuses on home- and community-based pharmacy and provider health solutions for complex and high-need populations. The BrightSpring news feed on Stock Titan aggregates company announcements, financial updates, and operational developments that the company discloses through press releases and other public channels.
Investors and observers following BTSG news can see regular updates on quarterly financial results, including segment performance for Pharmacy Solutions and Provider Services, as well as guidance ranges that the company provides for revenue and non-GAAP measures such as Adjusted EBITDA. BrightSpring’s news often highlights how it separates its continuing operations from its Community Living business, which it has agreed to divest to Sevita, and how this affects reported figures and outlook.
Beyond earnings releases and guidance changes, BrightSpring news includes information on capital markets activity, such as secondary offerings of common stock by existing stockholders under an automatic shelf registration statement, and any related share repurchases by the company. These announcements provide context on BTSG’s ownership structure and trading dynamics without involving primary share issuance by BrightSpring.
Sector-specific updates also appear in the news flow, including developments in BrightSpring’s specialty pharmacy operations. For example, the company has reported that its specialty pharmacy brand Onco360 has been selected as a national pharmacy partner for newly approved therapies in advanced cancers and rare genetic disorders, reflecting BrightSpring’s involvement in complex treatment areas.
By reviewing the BTSG news page, readers can track how BrightSpring describes its operational focus on complex populations, its integrated pharmacy and provider services, and the risk and regulatory factors it highlights in connection with its financial and strategic communications.
BrightSpring Health Services (NASDAQ: BTSG) has announced the promotion of Jennifer Phipps to Chief Financial Officer, effective March 4, 2025, succeeding Jim Mattingly. Phipps, who brings over 20 years of healthcare financial experience, has served at BrightSpring for eight years in multiple roles including Chief Accounting Officer and CFO of the Home Health and Hospice segment.
During her tenure at BrightSpring, Phipps has led technology implementations to streamline financial processes, built a lean-focused procurement team, and implemented various accounting systems. She played a important role in the company's IPO and has maintained active involvement in public company processes. Prior to BrightSpring, she held leadership positions at Cardinal Health and spent six years at Ernst & Young.
Phipps holds a CPA license and received her Bachelor's and Master's in Accounting from The Ohio State University. She will lead BrightSpring's financial operations, supporting the company's mission of providing community-based pharmacy and provider health solutions to complex populations.
BrightSpring Health Services (NASDAQ: BTSG) has scheduled the release of its fourth quarter and full year 2024 financial results for Thursday, March 6, 2025, before market open. The company will host an earnings conference call at 8:30 a.m. ET on the same day.
Interested participants can register for the conference call online. A live and archived webcast of the call will be available on the company's investor relations website, along with related presentation materials which will be posted prior to the call.
BrightSpring Health Services (NASDAQ: BTSG) has announced the sale of its Community Living business to Sevita for $835 million in cash. The transaction, expected to close in 2025, will generate approximately $715 million in after-tax proceeds, primarily used for debt reduction.
The divested Community Living business is projected to generate about $1.2 billion in Revenue and $128 million in Adjusted EBITDA for 2024. Post-divestiture, BrightSpring will focus on Home Health/Hospice, Personal Care, Rehabilitation Services, and Primary Care.
The company reported preliminary 2024 results above previous guidance, with expected Net Revenue of $11.2-11.3 billion and Adjusted EBITDA of approximately $588 million. For 2025, excluding Community Living, BrightSpring projects Net Revenue of $11.5-12.0 billion and Adjusted EBITDA of $540-555 million.
BrightSpring Health Services (NASDAQ: BTSG) has successfully refinanced its entire $2.55 billion Term Loan B facility due February 2031 through its subsidiary Phoenix Guarantor Inc. The refinancing resulted in a reduced interest rate, with the facility now priced at SOFR +250 basis points, down from SOFR +325 basis points. This 75 basis point reduction is expected to generate annual cash interest savings of approximately $19.1 million. The transaction was completed without incurring any additional debt, with Morgan Stanley and KKR Capital Markets acting as lead bookrunners.
BrightSpring Health Services (NASDAQ: BTSG) announces that its specialty pharmacy partner, Onco360®, has been selected as the national pharmacy partner for multiple new medications treating advanced cancers and blood diseases. Eight new medications have been added to Onco360's distribution network, including treatments for: breast cancer (ITOVEBI™), myelodysplastic syndromes (Rytelo™), brain tumors (Voranigo®), paroxysmal nocturnal hemoglobinuria (PIASKY®), esophageal cell carcinoma (Tevimbra®), non-small cell lung cancer (LAZCLUZE™), acute leukemias (Revuforj®), and gastric tumors (Vyloy®).
BrightSpring Health Services (NASDAQ: BTSG) has announced its participation in two upcoming virtual investor conferences. The company will take part in the BTIG Virtual Digital Health Forum Panel on November 25th at 9:00 AM ET and the Bank of America Virtual Home Care Conference 2024 Fireside Chat on December 10th at 2:10 PM ET. A live and archived webcast of the Bank of America conference session will be accessible through BrightSpring's investor relations website.
BrightSpring Health Services (NASDAQ: BTSG) announced that its subsidiary CareMed has been selected by Eisai as a national specialty pharmacy provider for Leqembi®, an innovative Alzheimer's disease treatment. The FDA-approved medication demonstrated effectiveness in slowing cognitive impairment progression over 18 months in Phase III clinical trials involving 1,795 patients aged 50-90 with early Alzheimer's disease. Leqembi is a monoclonal antibody targeting aggregated forms of amyloid beta, showing superior results compared to placebo in treating mild cognitive impairment and mild dementia stages.
BrightSpring Health Services reported strong Q3 2024 financial results with net revenue of $2,907 million, up 28.8% year-over-year. The company reduced its net loss to $9.0 million from $130.1 million in Q3 2023, while Adjusted EBITDA grew 15.7% to $151 million. Pharmacy Solutions revenue increased 35% to $2,266 million, and Provider Services revenue grew 10% to $641 million. Based on strong performance, BrightSpring increased its full-year 2024 guidance, projecting revenue of $11,000-$11,300 million (24.6-28.0% growth) and Adjusted EBITDA of $580-$585 million (14.2-15.2% growth).
BrightSpring Health Services, Inc. (NASDAQ: BTSG) has announced plans to release its third quarter 2024 financial results on Friday, November 1, 2024. The company will hold an earnings conference call at 8:30 a.m. ET on the same day. Interested parties can register for the call through the provided link. A live and archived webcast of the call will be available on the company's investor relations website at https://ir.brightspringhealth.com under the 'Events & Presentations' section. Related presentation materials will be posted prior to the conference call. The webcast can also be accessed directly through a provided link.
BrightSpring Health Services (NASDAQ: BTSG) has appointed Dr. Steve Miller as a Class II member of its Board of Directors. Dr. Miller will serve on the Board's Audit Committee and chair the Quality & Compliance and Governance Committee. With decades of experience as a medical researcher, clinician, and administrator, Dr. Miller brings valuable expertise to BrightSpring.
Dr. Miller's notable career includes roles as Chief Clinical Officer at Cigna (2018-2022), Chief Medical Officer at Express Scripts (2005-2018), and Chief Medical Officer at Barnes-Jewish Hospital (1999-2005). He is currently the Chief Medical Officer at MediBeacon, a medical technology company.
BrightSpring's CEO, Jon Rousseau, expressed excitement about Dr. Miller joining the board, highlighting his unique insights into patient success. Dr. Miller stated his commitment to making a difference in healthcare and bringing his perspective to drive innovation at BrightSpring.